Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 512-516

  Bokemeyer, C ^a   Gerl, A ^a   Schoffski P ^a   Harstrick, A ^a   Niederle, N ^a   Beyer, J ^a   Casper, J ^a   Schmoll, H J ^a   Kanz, L ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MECHANISM; DRUG RESPONSE; FEVER; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NON SEMINOMATOUS GERMINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TESTIS CANCER; THROMBOCYTOPENIA; VOMITING;

EID: 0033044108     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.512     Document Type: Article

References (26)

1. Bosl GJ, Motzer RJ: Testicular germ cell cancer. N Engl J Med 337:242-253, 1997
2. Einhorn LH: Treatment of testicular cancer: A new and improved model. J Clin Oncol 8:1777-1781, 1990
3. Nichols CR, Tricot G, Williams S, et al: Dose-intensive chemotherapy in refractory germ cell cancer: A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7:932-939, 1989
4. Siegert W, Beyer J, Strohscheer I, et al: High-dose treatment with carboplatin, etoposide and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study. J Clin Oncol 12:1223-1231, 1994
5. Nichols CR, Roth BJ, Loehrer PJ, et al: Salvage chemotherapy for recurrent germ cell cancer. Semin Oncol 5:102-108, 1994 (suppl 12)
6. Motzer RJ, Mazumdar M, Bosl GJ, et al: High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14:1098-1105, 1996
7. Bokemeyer C, Droz J-P, Hanauske A, et al: Treatment of relapsed nonseminomatous germ cell tumors with vinorelbine: A trial of the Phase I/II Study Group of the Association for Medical Oncology of the German Cancer Society. Onkologie 16:29-31, 1993
8. Puc HS, Bajorin DF, Bosl GJ, et al: Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Invest New Drugs 13:163-165, 1995
9. Harstrick A, Schmoll H-J, Wilke H, et al: High-dose epidoxorubicin in refractory or relapsed nonseminomatous testicular cancer: A phase II study. Ann Oncol 2:375-376, 1990
10. Bokemeyer C, Beyer J, Metzner B, et al: Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7:31-34, 1996
11. Motzer RJ, Bajorin DF, Schwartz LH, et al: Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12:2277-2283, 1994
12. Sandler AB, Cristou A, Fox S, et al: A phase II trial of paclitaxel in refractory germ cell tumors. Cancer 82:1381-1386, 1998
13. Bokemeyer C, Hartmann JT, Kuczyk MA, et al: Recent strategies for the use of paclitaxel in the treatment of urological malignancies. World J Urol 16:155-162, 1998
14. Motzer RJ, Bajorin DF, Bosl GJ, et al: Paclitaxel (T) containing first-line salvage therapy selected by risk for patients (pts) with germ cell tumors (GCT). Proc Am Soc Clin Oncol 16:322a, 1997 (abstr 1146)
15. Motzer RJ, Green GA, McCaffrey JA, et al: Paclitaxel (T), ifosfamide (I), and cisplatin (P) as first-line salvage therapy for relapsed germ cell tumor (GCT) patients with favorable prognostic features. Proc Am Soc Clin Oncol 17:322a, 1998 (abstr 1241)
16. De Wit R, Louwerens M, De Mulder PHM, et al: A dose finding study of paclitaxel (Taxol) added to fixed doses of bleomycin, etoposide, cisplatin (BEP) in patients with adverse prognosis germ cell cancer or carcinoma of unknown primary (CUP). Proc Am Soc Clin Oncol 17:322a, 1998 (abstract 1240)
17. Beyer J, Bokemeyer C, Rick O, et al: Salvage treatment in germ-cell tumors using Taxol, ifosfamide, cisplatin (TIP) followed by high-dose carboplatin, etoposide and thiotepa (HDCET): First results. Proc Am Soc Clin Oncol 17:322a, 1998 (abstract 1242)
18. Maas K, Daikeler T, Kanz L, et al: Activity of gemcitabine in platinum-resistant ovarian germ cell cancer. Eur J Cancer 32A:1437-1438, 1996
19. Plunkett W, Huang P, Xu YZ, et al: Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3-10, 1995
20. Noble S, Goa KL: Gemcitabine: A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 54:447-472, 1997
21. Stadler WM, Kuzel T, Roth B, et al: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394-3398, 1997
22. Einhorn LH: Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: A Hoosier Oncology Group study. Semin Oncol 24:S8:24-26, 1997
23. Gatzemeier U, Shepherd FA, Le Chevalier T, et al: Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study. Eur J Cancer 32A:243-248, 1996
24. Carmichael J, Possinger K, Philip P, et al: Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 13:2731-2736, 1995
25. Slender MJ, Loehrer PJ, Williams SD, et al: A phase II trial of gemcitabine in relapsed/refractory germ cell tumor (GCT). Proc Am Soc Clin Oncol 17:321a, 1998 (abstr 1238)
26. Huang P, Plunkett W: Induction of apoptosis by gemcitabine. Semin Oncol 22:19-25, 1995